The present invention relates to conjugates targeting uPARAP, in particular antibody-drug conjugates (ADCs) comprising monoclonal antibodies directed against the N-terminal region of uPARAP, and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as cancer.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
The present disclosure relates to agonists of Tacr2, such as peptides agonist of Tacr2 and methods of using the same for treatment of insulin resistance, obesity and/or diabetes. The disclosure also relates to use of said agonists of Tacr2 for enhancement of energy consumption in an individual.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 5/50 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques pour augmenter ou potentialiser l'activité de l'insuline
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present invention relates to a method of quantifying methane removal in the atmosphere. Specifically, the present invention relates to quantifying methane removal by iron-salt aerosols. The present invention also relates to the method for use for the purpose of claiming a carbon credit.
The present invention relates to isolated polypeptides derived from stanniocalcin-2 (STC2), and polypeptide fragments and variants thereof useful for inhibiting proteolytic activity of the pregnancy-associated plasma protein-A (PAPP-A), as well as methods for identifying ligands and inhibitors of PAPP-A.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C12N 15/75 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes procaryotes autres que E. coli, p.ex. Lactobacillus, Micromonospora pour Bacillus
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p.ex. hyaluronidase, invertase, amylase
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Flood, Amar H.
Yadav, Ravindra Kumar
Satapathy, Sitakanta
Deshmukh, Prathmesh
Menon, Vinod
Laursen, Bo
Abrégé
Disclosed herein is a microcavity comprising a photoluminescent material positioned between two reflectors, wherein the photoluminescent material comprises a cationic molecular dye, a macrocyclic anion receptor host, and an anion embedded within the macrocyclic anion receptor host and methods of making and using the same.
C07C 255/49 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné
C07C 255/58 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au squelette carboné
C07D 209/56 - Systèmes cycliques contenant au moins trois cycles
H10K 85/60 - Composés organiques à faible poids moléculaire
H10K 50/11 - OLED ou diodes électroluminescentes polymères [PLED] caractérisées par les couches électroluminescentes [EL]
8.
A FLEXIBLE FOIL FOR THE DELIVERY OF THERAPEUTIC CARGOS
The present invention relates to a drug delivery platform. In particular, it relates to a foil-based drug delivery platform for delivery to the intestine.
INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (République de Corée)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Na, Kyung Su
Choi, Yu Yeol
Lee, Ji Woong
Milia, Marco
Abrégé
22) is inhibited by the chloride ion adsorbent while producing hydrogen without treating seawater to freshwater. In the absence of the chloride ion adsorbent, otherwise, a large amount of chloride ions (Cl-) will be oxidized during electrolysis due to NaCl dissolved in a large amount in seawater.
B01J 20/10 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant de la silice ou un silicate
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
The present invention relates to co-amorphous form of a substance and a protein. The present invention also relates to pharmaceutical, cosmetic or veterinary compositions comprising the co-amorphous form as well as to methods for preparing and using the co-amorphous form.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol o
11.
LYSOSOMAL ENZYMES MODIFIED BY CELL BASED GLYCOENGINEERING
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
C12N 9/40 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-galactose-glycoside, p.ex. alpha-galactosidase
C12P 21/00 - Préparation de peptides ou de protéines
12.
STENCIL MASK AND USE THEREOF IN LITHOGRAPHY FABRICATION
The disclosure relates to a stencil mask, a method for manufacturing the stencil mask and use of the stencil mask in nanoscale device nanofabrication, including imprinting on substrates of deposition patterns for nanoscale devices. One embodiment relates to a stencil mask for manufacturing at least one nanoscale device on a substrate, the stencil mask comprising, a membrane having a top surface and bottom surface and a thickness therebetween of at least 500 nm, a predefined pattern of apertures extending through the membrane, each aperture having a width and a length in the top surface of the membrane, wherein at least the width and/or the length of one of said apertures is of less than 100 nm, each aperture defined by inner sidewalls extending between the top surface and the bottom surface of the membrane, and a set of separating nanostructures on the top surface of the membrane for separating the top surface of the membrane from a top surface of the substrate.
G03F 1/20 - Masques ou masques vierges d'imagerie par rayonnement d'un faisceau de particules chargées [CPB charged particle beam], p.ex. par faisceau d'électrons; Leur préparation
C23C 14/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C23C 16/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C23C 18/16 - Revêtement chimique par décomposition soit de composés liquides, soit de solutions des composés constituant le revêtement, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement; Dépôt par contact par réduction ou par substitution, p.ex. dépôt sans courant électrique
in vivoin vivoin vivo neuron maturation/differentiation and/or vagus nerve modulation by administering a therapeutic amount of a composition comprising IGF-1, for example in a complex with an IGF-1 binding protein, such as IBGBP-3.
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present invention relates to virally expressed peptides which bind to PDZ domains and thereby block PDZ domain mediated protein-protein interactions and expression vectors encoding these peptides. The virally expressed peptides comprise an oligomerization domain, capable of forming higher order constructs, such as trimers or tetramers, and a peptide ligand capable of binding to a PDZ domain. The invention furthermore relates to therapeutic use of said peptides and expression vectors encoding these peptides.
The present disclosure relates to a lipid conjugated bivalent peptide ligand which bind to Protein Interacting with C Kinase-1 (PICK1) and thereby inhibit PICK1. The PICK1 inhibitors of the present disclosure comprise a peptide portion comprising two peptide ligands of PICK1, and a non-peptide portion comprising a linker, linking the two peptide ligands, and a lipid. The disclosure furthermore relates to therapeutic and diagnostic use of said PICK1 inhibitor for treatment of diseases or disorders associated with maladaptive plasticity.
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
17.
BIODEGRADABLE COMPOSITE MATERIAL OF PURE AMYLOSE AND CELLULOSE NANOFIBRES OR CELLULOSE NANOCRYSTALS
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 209/94 - Systèmes cycliques contenant au moins trois cycles condensés en [b, c] ou [b, d] contenant des carbocycles autres que des cycles à six chaînons
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
The present disclosure relates to compounds which bind Ca2+/calmodulin dependent protein kinase II. It also relates to such compounds for use in the treatment of CNS disorders with sleep disturbances and acute brain injury.
C07D 277/06 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 277/12 - Composés hétérocycliques contenant des cycles thiazole-1, 3 ou thiazole-1, 3 hydrogénés non condensés avec d'autres cycles comportant une liaison double entre chaînons cycliques ou entre chaînon cyclique et chaînon non cyclique avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 277/56 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène
C07D 417/04 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with complementary inverse electron demand Diels-Alder cycloaddition reactivity, which upon ligation, followed by oxidation, will form compounds of a single isomeric form. The labeled single isomeric chemical entity targeting vectors are for use in therapy, radiotherapy, theranostics, diagnostics, and imaging. The method applies click chemistry wherein one chemical entity which is conjugated to a label is clicked together with a second chemical entity with complementary inverse electron demand Diels-Alder cycloaddition reactivity which is conjugated to a targeting vector followed by a rapid oxidation, to form a single isomeric compound.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
C07D 209/94 - Systèmes cycliques contenant au moins trois cycles condensés en [b, c] ou [b, d] contenant des carbocycles autres que des cycles à six chaînons
C07D 241/42 - Benzopyrazines avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone de l'hétérocycle
C07D 257/10 - Composés hétérocycliques contenant des cycles comportant quatre atomes d'azote comme uniques hétéro-atomes du cycle condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 209/52 - Composés hétérocycliques contenant des cycles à cinq chaînons condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle condensés avec un carbocycle condensés avec un cycle autre qu'un cycle à six chaînons
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A betalain pigment composition from red beet plants including pre-harvest foliar spraying of an ethylene-generating compound and the use of the obtained betalain pigment composition for coloring of an edible product
A23L 5/43 - Adjonction de colorants ou de pigments, p.ex. en combinaison avec des azurants optiques en utilisant des colorants ou des pigments organiques d'origine naturelle, leurs doublons artificiels ou leurs dérivés
A23K 20/179 - Agents colorants, p.ex. agents de pigmentation ou de teinture
A01G 22/25 - Légumes-racines, p.ex. pommes de terre, ignames, betterave ou wasabi
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
26.
ISOLATION OF BONA FIDE PANCREATIC PROGENITOR CELLS
The present invention relates to a method for isolating bona fide pancreatic progenitor cells and to cell populations enriched for bona fide pancreatic progenitor cells.
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
A61P 3/08 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
27.
CYCLIC PEPTIDE INHIBITORS OF PSD-95 AND USES THEREOF
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present disclosure regards a qubit circuit comprising at least first and second data qubits and a mediator qubit coupling the first and second data qubits in a circuit plane, wherein the first data qubit and the second data qubit are coupled to the mediator qubit by means of respective twist couplers, each twist coupler comprising superconducting regions connected by superconducting transmission lines, wherein at least two of the connecting transmission lines cross each other at a line crossing point where the crossing transmission lines are separated by an insulator layer.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate-specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
According to the invention there is provided methods for making heparan sulfate with increased anticoagulant activity wherein the resulting product has a lower heterogeneity and presents an improved safety profile compared to conventional animal‐sourced heparin.
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 27/00 - Médicaments pour traiter les troubles des sens
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
34.
REJUVENATION TREATMENT OF AGE-RELATED WHITE MATTER LOSS
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
35.
ISOLATED GLIAL PROGENITOR CELLS FOR USE IN THE COMPETITION TREATMENT OF AGE-RELATED WHITE MATTER LOSS
The present application relates to alleviating adverse effects of oligodendrocyte loss, astrocyte loss, or white matter loss, including age-related oligodendrocyte loss, age-related astrocyte loss, or age-related white matter loss, in the brain of a subject. The present application also relates to rejuvenating a glial progenitor cell or a progeny thereof, or to enhancing the development potential of a glial progenitor cell or a progeny thereof.
A61P 25/02 - Médicaments pour le traitement des troubles du système nerveux des neuropathies périphériques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 27/00 - Médicaments pour traiter les troubles des sens
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
36.
HUMANIZED CHIMERAS FOR THE PROSPECTIVE ASSESSMENT OF GLIAL CELL ADDITION OR REPLACEMENT THERAPY
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
A chimeric non-human mammal disease model, wherein (1) at least 30% of all the glial cells in the corpus callosum of the chimeric non-human mammal are human glial cells, and/or (2) at least 5% of all of the glial cells in the white matter of the brain and/or brain stem of the chimeric non-human mammal are human glial cells, and wherein the human glial cells comprise a combination of a first group of human glial cells tagged with a first label and a second group of human glial cells tagged with a second label that is distinguishable from the first label.
Nederlands Instituut voor Ecologie (Nioo-Knaw) (Pays‑Bas)
University of Copenhagen (Danemark)
Inventeur(s)
De Bruijn, Irene
Raaijmakers, Josephus Maria
Buchman, Kurt
Abrégé
The invention relates to the use of bacterial lipopeptide biosurfactants in the treatment of white spot disease in fresh water and marine fish. Particularly useful for treatment of white spot disease are viscosin-like lipopeptide biosurfactants obtainable from the Pseudomonas fluorescens strain H6, massetolide or a derivative thereof and putisolvin or a derivative thereof.
The invention relates to a virus-like particle (VLP) based vaccine. The virus-like particle constitutes a non-naturally occurring, ordered and repetitive antigen array display scaffold which can obtain a strong and long-lasting immune response in a subject. The VLP-based vaccine may be used for the prophylaxis and/or treatment of a disease including, but is not limited to, cancer, cardiovascular, infectious, chronic, neurological diseases/disorders, asthma, and/or immune-inflammatory diseases/disorders.
The present invention relates to a method for preparing gold nanoparticles and nanomaterials without the need for organic adsorbates having a molar mass above 100 g/moL The present invention also relates to a colloidal dispersion of the gold nanoparticles obtained by the methods according to the invention, solid and redispersed nanomaterials and products comprising gold nanoparticles.
B22F 1/00 - Poudres métalliques; Traitement des poudres métalliques, p.ex. en vue de faciliter leur mise en œuvre ou d'améliorer leurs propriétés
B22F 9/16 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique
B22F 1/0545 - Dispersions ou suspensions de particules de taille nanométrique
B22F 9/24 - Fabrication des poudres métalliques ou de leurs suspensions; Appareils ou dispositifs spécialement adaptés à cet effet par un procédé chimique avec réduction de mélanges métalliques à partir de mélanges métalliques liquides, p.ex. de solutions
41.
A METHOD OF MANIPULATING A QUBIT AND AN ASSEMBLY COMPRISING A QUBIT
An assembly comprising a qubit and a method of altering a qubit, where a presence of a charge in a storage element close to the qubit influences on the state in which the altering is performed. Then, altering may be performed by feeding signals to electrodes, where the same signal is fed to the qubit but where the state is altered only if the charge is present in the storage element. Multiple qubits may then receive the same signal and only the ones with a charge are altered by the signal.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
A circuit for transferring charge, which may be in the form of charged particles from a first storage element to one of a plurality of second storage elements, the circuit comprising a circuit element configured to receive the charge or charged particles and deliver the charge or charged particles to an identified one of the plurality of second storage elements. The charge delivered may be the same charged particles or other charged particles. The circuit may be used for embodying Boolean circuits or gates operable at cryo temperatures.
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
G06N 10/00 - Informatique quantique, c. à d. traitement de l’information fondé sur des phénomènes de mécanique quantique
H01L 27/18 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des composants présentant un effet de supraconductivité
The present invention relates to designed water for brewing of coffee. Specifically the designed water of the invention can be used to prepare good-tasting coffee.
A23F 5/24 - Extraction du café; Extraits de café; Fabrication du café instantané
A23F 5/26 - Extraction des constituants solubles dans l'eau
A23L 33/16 - Sels inorganiques, minéraux ou oligo-éléments
C02F 1/66 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par neutralisation; Ajustage du pH
C02F 1/68 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par addition de substances spécifiées, pour améliorer l'eau potable, p.ex. par addition d'oligo-éléments
44.
A METHOD FOR DETERMINING A CHARGE-STATE BOUNDARY OF A QUANTUM DOT, A MULTI-DOT DEVICE, OR AN ARRAY OF QUANTUM DOTS AND A DATA PROCESSING SYSTEM FOR PERFORMING THE METHOD
The invention regards a method for determining a charge-state boundary of a quantum dot, a multi-dot device, or an array of quantum dots, comprising the steps of defining an initial point inside a charge state of a quantum dot having a charge-state boundary, ramping gate voltages from the initial point thereby creating a plurality of rays in gate voltage space, creating a time stamp when each of the rays leave the charge-state / cross the charge-state boundary, and constructing the boundary of the charge state by correlating each ray in gate voltage space with the associated time stamp.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
45.
A METHOD FOR DETERMINING A CHARGE-STATE BOUNDARY OF A QUANTUM DOT, A MULTI-DOT DEVICE, OR AN ARRAY OF QUANTUM DOTS AND A DATA PROCESSING SYSTEM FOR PERFORMING THE METHOD
The invention regards a method for determining a charge-state boundary of a quantum dot, a multi-dot device, or an array of quantum dots, comprising the steps of defining an initial point inside a charge state of a quantum dot having a charge-state boundary, ramping gate voltages from the initial point thereby creating a plurality of rays in gate voltage space, creating a time stamp when each of the rays leave the charge-state / cross the charge-state boundary, and constructing the boundary of the charge state by correlating each ray in gate voltage space with the associated time stamp.
G01N 27/22 - Recherche ou analyse des matériaux par l'emploi de moyens électriques, électrochimiques ou magnétiques en recherchant l'impédance en recherchant la capacité
inter aliainter alia, to complexes of the Na+ leak channel non-selective protein (NALCN) with FAM155A (also called FAM155; Family with sequence similarity 155 member A), UNC79 (uncoordinated 79), and UNC80 (uncoordinated 80), methods of screening for molecules that modulate the activity of the complex, and identified modulators thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
47.
METHOD FOR PRODUCING THE SESQUITERPENE VIRIDIFLOROL WITH A FUNGAL ENZYME
Board of Trustees of Michigan State University (USA)
University of Copenhagen (Danemark)
Inventeur(s)
Ntana, Fani
Collinge, David B.
Hamberger, Björn
Bhat, Wajid Waheed
Johnson, Sean
Jensen, Birgit
Jorgensen, Hans Jorgen Lyngs
Abrégé
Constructs, host cells, fungi, seeds, plants, and methods are described herein can include a Serendipita indica terpenoid synthase (SiTPS). Such constructs host cells, fungi, seeds, plants, and methods are useful, for example, for making viridiflorol. As described herein, the basidionycete Serendipita indica, a non-specific-host root endophyte fungus, possesses a functional terpenoid synthase gene (SiTPS). Heterologous expression of SiTPS in host cells showed that the produced protein efficiently utilizes the fifteen-carbon precursor farnesylpyrophosphate (FTP) to synthesize the sesquiterpene alcohol viridiflorol, shown below.
The present invention relates to humanized antibodies and molecular conjugates targeting Urokinase type plasminogen activator receptor associated protein (uPARAP), in particular antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as certain cancers.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
Provided is a quantum computing device comprising a carbon nanotube, a superconducting substrate in quantum proximity to the nanotube and being in a superconducting state having a pairing correlation matrix with a substantial spin-triplet component in a direction perpendicular to the nanotube, and a magnet arranged to provide a longitudinal magnetic field along a longitudinal axis of the nanotube. Further provided is a quantum computing device comprising at least three substrates made of a superconductor material and each in a superconducting state, and a non-superconducting structure made of a material in which the electrons' closed trajectories experience strong spin-orbit coupling interactions and being in quantum proximity to the substrates. The sum of the phase differences between the order parameters of all of the substrates is at least π.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
H01L 39/12 - Dispositifs utilisant la supraconductivité ou l'hyperconductivité; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives - Détails caractérisés par le matériau
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
50.
ANTIBODY-DRUG CONJUGATES COMPRISING HUMANIZED ANTIBODIES TARGETING UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR ASSOCIATED PROTEIN (UPARAP)
The present invention relates to humanized antibodies and molecular conjugates targeting Urokinase type plasminogen activator receptor associated protein (uPARAP), in particular antibody-drug conjugates (ADCs) comprising humanized antibodies directed against uPARAP and their use in delivery of active agents to cells and tissues expressing uPARAP. The invention further relates to the use of said ADCs in the treatment of diseases involving uPARAP expressing cells, such as certain cancers.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to non-naturally occurring antibodies or active antibody fragments specifically binding the calcium-sensing receptor (CaSR), acting as positive allosteric modulators (PAMs) to provide for potent therapeutic agents. More particular, the immunoglobulin single variable domains (ISVDs) identified herein reveal a novel therapeutic strategy to reduce parathyroid hormone release in a subject, and are therefore suitable for treatment of hypercalcemia disorders. Moreover, co-application of such an ISVD and a synthetic PAM or calcimimetic results in a synergistic agonistic CaSR activity providing for pharmaceutical compositions as next generation CaSR drugs.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 5/20 - Médicaments pour le traitement des troubles du système endocrinien des hormones parathyroïdiennes pour réduire, bloquer ou contrarier l'activité de la PTH
52.
A UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-TARGETING PEPTIDE
The present invention describes a uPAR-targeting peptide conjugate comprising a fluoro bore, a peptide binding to uPAR and a linker group which are connected by covalent bonds, wherein the uPAR-targeting peptide conjugate may be used as fluorescence probe in real time optical imaging and delineation of cancer tumors or metastases during surgery.
The invention concerns a compound of formula (I), a pharmaceutical formulation comprising the compound of formula (I) and use of the pharmaceutical composition for treating fibrotic, inflammatory, diabetic or cognitive disease.
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4433 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'oxygène comme hétéro-atome du cycle
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p.ex. antidiabétiques
A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).
The present invention relates to mutant Cas12j (also known as CasΦ) endonucleases having altered activity or improved properties compared to the corresponding wild type Cas12j endonuclease, as well as methods using the mutant Cas12j endonucleases.
The present invention relates to polypeptides derived from Ruminococcus torques, and polypeptide fragments and variants thereof useful for treatment and/or prevention of metabolic disorders, muscle disorders and injuries, and bone disorders, and host cells comprising said polypeptides, polypeptide fragments or variants thereof for use as a probiotic or as a Live Biopharmaceutical Product (LBP).
There are provided compositions and mucin-binding targeting agents derived from microbial proteins that have selective binding properties for densely glycosylated mucins as well as such compositions and targeting agents comprising a binding moiety and/or a payload which may be attached to the binding moiety or directly to a targeting agent. The compositions and targeting agents may be used as medicaments in the treatment of a disease, illness, or disorders.
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C07K 14/33 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Clostridium (G)
The present invention relates to mutant Cas12j (also known as Cas?) endonucleases having altered activity or improved properties compared to the corresponding wild type Cas12j endonuclease, as well as methods using the mutant Cas12j endonucleases.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
61.
METHOD FOR CONTROLLING GROWTH OF MICROORGANISMS AND/OR BIOFILMS IN AN INDUSTRIAL PROCESS
The invention relates to a method for controlling of a biofilm, for removing a formed biofilm and/or for controlling a growth of microorganisms, preferably bacteria, in an aqueous environment of an industrial manufacturing process comprising cellulosic fibre material. In the method a composition comprising a compound selected from a group consisting of 3-[(4-methylphenyl)sulphonyl]-2-propenenitrile and 4-amino-N-2-thiazolyl-benzenesulphonamide is administered to the aqueous environment of the process.
The present invention relates to compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.
C07K 5/103 - Tétrapeptides la chaîne latérale du premier amino-acide étant acyclique, p.ex. Gly, Ala
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 5/113 - Tétrapeptides la chaîne latérale du premier amino-acide contenant plus de groupes carboxyle que de groupes amino, ou leurs dérivés, p.ex. Asp, Glu, Asn
A device for generating individual photons with energy E includes quantum emitters, having at least one determined transition with the energy E from an energy level N* to a lower energy level N1. The emitters are near a propagation path running from first to second regions. The device also includes at least one light source to output light, for propagation along the path. The light has the energy E for resonant excitation of the energy level N*. The emitters are arranged so that optionally exactly Z emitters are illuminated, forming an optical thickness τ>0 for the light along the path. The number Z lies in a range of Z0±10% and Z0 is a number at which a maximum destructive interference in the second region occurs between a two-photon component of the light scattered on the ZO emitters and a two-photon component of the non-scattered light.
A system (10, 21) for determining information relating to a first periodic signal, the system comprising a sequence of storage elements (12, 14) each configured to store at least one charged particle, where a signal with a constant voltage, V1 DC, V2 DC, and a signal with a varying voltage, V1 AC, V2 AC, is fed to each storage element. One of the signals with the varying voltage is the first periodic signal. By monitoring the current,I, pumped between the storage elements by the voltages applied to the storage elements, the information relating to the first periodic signal may be generated.
G01R 15/16 - Adaptations fournissant une isolation en tension ou en courant, p.ex. adaptations pour les réseaux à haute tension ou à courant fort utilisant des dispositifs capacitifs
65.
SMALL HYDROPHOBIC PROTEIN DRUG CONJUGATES AND USES THEREOF
The present disclosure provides peptide conjugated drugs based on MuV SH Protein, their use as therapeutic agents and their use to provide delivery to and/or transfer across a membrane of the drug. The present disclosure provides use of the peptide conjugated drug for delivery of the drug to and/or across a membrane harbouring G protein-coupled receptor 125 (GPR125), such as the choroid plexus.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
66.
TREATMENT OF CNS DISORDERS WITH SLEEP DISTURBANCES
A compound for use in the treatment of CNS disorders with sleep disturbances e.g. narcolepsy or Angelman syndrome in a subject, wherein said compound is according to formula (I) or any isomer, tautomer, enantiomer, racemic form or deuterated form thereof, or a pharmaceutically acceptable salt thereof.
A sensor for a cryogenic operated device, the set-up comprising dual quantum dots positioned so close to a conductor supplying an electrical signal to the device. A charged particle (32) in the quantum dots is affected and moved due to the field, so that detection of the position of the particle will provide information relating to the field and thus the signal.
The present disclosure relates to a method of manufacturing a transferable lamella comprising interconnected nanostructures, the method comprising the steps of: a)providing a substrate such as a planar substrate; b) forming at least one superstructure on the substrate, said superstructure comprising a plurality of elongated nanostructures (formed e.g. by growth, deposition, and/or etching); wherein the elongated nanostructures are formed such that at least two of said nanostructures are conductively interconnected, and/or wherein at least a first layer is grown or deposited to conductively interconnect or insulate at least a part of the elongated nanostructures; c) encapsulating at least a portion of said superstructure in an encapsulating material, said portion comprising at least two interconnected nanostructures; and d) cutting the encapsulating material in a direction that intersects at least two interconnected nanostructures, thereby manufacturing a transferable lamella comprising interconnected nanostructures. The present disclosure further relates to an electronic device manufactured from one or more of the lamellas provided by the method.
C30B 29/60 - Monocristaux ou matériaux polycristallins homogènes de structure déterminée caractérisés par leurs matériaux ou par leur forme caractérisés par la forme
H01L 39/22 - Dispositifs comportant une jonction de matériaux différents, p.ex. dispositifs à effet Josephson
H01L 29/66 - Types de dispositifs semi-conducteurs
The invention provides methods for identifying biomarkers in a patient's microbiota to predict a patient's response to a predetermined diet to promote weight loss and methods of promoting weight loss or treating obesity in the patient by optimizing the patient's diet in accordance with the biomarkers identified in the patient's gut microbiota. The methods of the invention can also be used to manage or maintain weight, i.e., prevent or inhibit weight gain, in a patient who is of normal weight or is overweight or obese.
C12Q 1/40 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase une amylase
A61P 3/04 - Anorexigènes; Médicaments de l'obésité
A23L 33/00 - Modification de la qualité nutritive des aliments; Produits diététiques; Leur préparation ou leur traitement
71.
ALIPHATIC 18F-RADIOLABELING OF A TETRAZINE PRECURSOR
NN2. Unfortunately, these structures display too low reactivity for in vivo bioorthogonal chemistry approaches. Highly reactive structures such as mono-unsubstituted tetrazines (H-Tzs) have been reported to be highly sensitive to base. Extensive degradation is observed which prevents isolation of meaningful amounts for imaging studies. In the present invention there is provided a method providing the possibility to radiolabel base sensitive tetrazine structures with significantly improved RCYs. Even tetrazines that were previously not accessible by applying "standard" aliphatic 18F-labeling strategies can be radiolabeled. This places new classes of 18F-fluorinated compounds within reach for application in PET imaginge studies such as for diagnosis of cancers.
C07B 59/00 - Introduction d'isotopes d'éléments dans les composés organiques
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present invention relates to mutated bacterial host cells, said host cells producing a polypeptide of interest and having at least one disrupted flagellum gene, and to nucleic acid constructs and vectors encoding at least one flagellum polypeptide with reduced or eliminated activity as well as to methods of producing one or more polypeptide of interest in said host cells.
C12N 9/26 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-glucosidiques-1, 4, p.ex. hyaluronidase, invertase, amylase
C07K 14/32 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Bacillus (G)
C12N 9/24 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2)
The present invention relates to modular nanoparticle-based compositions based on nucleic acids, such as DNA and RNA, which are particularly useful in prophylaxis and/or treatment of diseases and disorders.
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present disclosure relates to methods for assessing the effects of a mutation of interest in a cell. Herein are also disclosed systems for assessing the effects of a mutation of interest in a cell. The disclosure also provides host cells and host cell populations comprising the system.
The present disclosure further relates to nanostructures, in particular hybrid nanostructures with patterned growth of various layers for use in nanoscale electronic devices, such as hybrid semiconductor nanostructures with patterned growth and/or deposition of superconducting material for use in quantum devices. The presently disclosed method can be utilized for in-situ manufacturing of nanoscale electronic devices that have not been contaminated by ex-situ processes. One embodiment relates to a method for manufacturing a substrate for growth of crystalline nanostructures, the method comprising the steps of: depositing one or more layers of a crystal growth compatible dielectric material, such as silicon oxide, in a predefined pattern on the surface of a crystal growth compatible substrate to create a predefined etch pattern of said crystal growth compatible material, and selectively etching the substrate surface around said etch pattern to provide at least one under-etched platform which is vertically raised from the etched substrate surface.
H01L 29/06 - Corps semi-conducteurs caractérisés par les formes, les dimensions relatives, ou les dispositions des régions semi-conductrices
H01L 39/24 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement des dispositifs couverts par ou de leurs parties constitutives
The present invention concerns a method for site-selective modification of a target protein or peptide by use of an acylation tag comprising a single lysine residue and at least three histidine residues. Upon contact with an acylating reagent, the target protein or peptide becomes modified at the ε-amine of the lysine residue of the acylation tag.
G01N 33/58 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des substances marquées
C07K 1/107 - Procédés généraux de préparation de peptides par modification chimique de peptides précurseurs
The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain.
C12N 9/40 - Hydrolases (3.) agissant sur les composés glycosyliques (3.2) agissant sur les liaisons alpha-galactose-glycoside, p.ex. alpha-galactosidase
C12P 21/00 - Préparation de peptides ou de protéines
The present invention relates to a vaccine comprising a nucleic acid construct such as a DNA construct especially a nucleic acid construct comprising sequences encoding invariant chain operatively linked to antigenic protein or peptide encoding sequences. The present vaccine stimulates an enhanced immune response.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
The invention regards a composite for environmental remediation, comprising: —one or more green rust compound(s) or green rust precursor(s), and—one or more biochar(s).
B01J 20/20 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant du carbone obtenu par des procédés de carbonisation
B01J 20/02 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique
B01J 20/06 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance inorganique contenant des oxydes ou des hydroxydes des métaux non prévus dans le groupe
B01J 20/30 - Procédés de préparation, de régénération ou de réactivation
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
Disclosed herein are composite materials comprising amylose, cellulose nanofibres or cellulose nanocrystals, and a plasticiser. The amylose is of high purity, specifically containing little or no amylopectin. The cellulose nanofibres or cellulose nanocrystals act to reinforce the disclosed composite materials. Also disclosed are methods of producing such composite materials, and their use.
The present invention provides extracorporeal removal of targeting vectors applied in pretargeted therapy and diagnostics in animals and humans. The method and the means for extracorporeal removal of the targeting vectors is based on binding agents with inverse electron demand Diels-Alder (IEDDA) cycloaddition reactivity. The targeting vector comprises a therapeutic agent, a diagnostic agent or a theranostic agent and a chemical entity with IEDDA reactivity whereas the extracorporeal means comprises a column with a biocompatible solid support to which a chemical entity with complementary IEDDA reactivity is attached.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
The present invention relates to virally expressed peptides with high affinity for the PDZ domains, such as the PDZ domain of PICK1. The invention furthermore relates to the therapeutic use of these peptides in prevention and/or treatment of diseases and/or disorders associated with maladaptive plasticity and/or transmission.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
The present invention relates to methods of modulating an activity of a Cas-effector on a target polynucleotide comprising contacting the Cas-effector with an inhibitor component, wherein the inhibitor component comprises an anti-CRISPR ribonucleotide sequence (acrRNA) capable of inhibiting the Cas-effector from (i) associating with a target nucleotide sequence; and/or (ii) associating with a CRISPR guide RNA, and thereby inhibiting the Cas-effector from forming an active RNA-guided Cas-effector complex.
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
The present invention relates novel cyclic peptides which can act as inhibitors of protein-protein interactions, specifically by inhibiting the PDZ2 domain of PSD-95, as well as their use in treatment of excitotoxic-related diseases and neuropathic pain.
The present invention relates to a technology and method of priming of an immune response using invariant chain linked antigen, when these are used to prime a subsequent booster immunization using any suitable vacci.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C12N 15/64 - Méthodes générales pour la préparation du vecteur, pour son introduction dans la cellule ou pour la sélection de l'hôte contenant le vecteur
91.
METHODS AND COMPOSITIONS RELATED TO LANTHANIDE-ENCODED MICROBEADS
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
UNIVERSITY OF COPENHAGEN (Danemark)
Inventeur(s)
Feng, Yinnian
White, Adam K.
Hein, Jamin B.
Fordyce, Polly M.
Abrégé
The present disclosure provides methods, devices, systems and kits for producing polymeric microbeads, including lanthanide-encoded microbeads. Among others, the present disclosure provides methods, systems and kits for producing functionalized microbeads that include on their surfaces amphipathic moieties with free reactive groups that remain free and can be used for covalently coupling molecules or moieties of inters to the microbeads.
A mechanical resonator device. The resonator device includes a resonator element made of an elastic material under tensile stress and adapted for sustaining at least one oscillation mode; and a clamping structure supporting the resonator element. The clamping structure has a phononic density of states exhibiting a bandgap or quasi-bandgap such that elastic waves of at least one polarisation and/or frequency are not allowed to propagate through the clamping structure. The resonator element and the clamping structure are configured to match with a soft-clamping condition that elastic waves of polarisation and/or frequency corresponding to the at least one oscillation mode of the resonator penetrate evanescently into the clamping structure in a manner such as to minimize bending throughout the entire resonator device. Thereby, bending related loss may be minimized and the Q-factor of the mechanical resonator may be maximized.
G01G 3/16 - Appareils de pesée caractérisés par l'utilisation d'organes déformables par élasticité, p.ex. balances à ressort dans lesquels l'élément de pesée est constitué par un corps solide soumis à une pression ou une traction pendant la pesée utilisant la mesure des variations de la fréquence des oscillations du corps
G01L 1/10 - Mesure des forces ou des contraintes, en général en mesurant les variations de fréquence d'éléments vibrants soumis à une contrainte, p.ex. de cordes tendues
93.
PSMA TARGETING UREA-BASED LIGANDS FOR PROSTATE CANCER RADIOTHERAPY AND IMAGING
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (Allemagne)
ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (Allemagne)
Inventeur(s)
Kjaer, Andreas
Herth, Matthias Manfred
Jensen, Andreas Ingemann
Eder, Matthias
Eder, Ann-Christin
Abrégé
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate?specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS (Allemagne)
ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (Allemagne)
Inventeur(s)
Kjær, Andreas
Herth, Matthias Manfred
Jensen, Andreas Ingemann
Eder, Matthias
Eder, Ann-Christin
Abrégé
The present invention provides novel PSMA targeting urea-based ligands that binds to prostate‐specific membrane antigen (PSMA) which is expressed 8-to-12-fold higher in prostate cancer cells when compared to healthy tissue. The PSMA targeting urea-based ligands comprises a chelating agent that may comprise a metal and a halogen radioisotope of fluorine, iodine, bromine or astatine. The invention further relates to a method for providing the PSMA targeting urea-based ligands of the invention, to precursors of the PSMA targeting urea-based ligands and to the PSMA targeting urea-based ligands use in radiotherapy, imaging and theranostic.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
Produits et services
Fertilizers; biological fertilizers. Biological fungicides for agricultural use; fungicides for
agricultural use; agricultural pesticides; biological
insecticides. Biotechnological research and development relating to
agriculture; agricultural research and development;
technical consultancy in the field of agricultural
pesticides and fertilizers; information services relating to
the safety of fertilisers and pesticides used in
agriculture.
96.
NUCLIDE LABELLED H-TETRAZINES AND USE THEREOF FOR PET AND SPECT PRETARGETED IMAGING AND RADIONUCLIDE THERAPY
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The compounds comprise a radionuclide of F, I or At and on or more polar groups providing that the compounds can efficiently react with extracellularly located pretargeting vectors and as such used for example for pretargeted cancer diagnostics and cancer therapy.
The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.
Provided herein are glucose-dependent insulinotropic polypeptide (GIP)-derived peptide analogues, for example GIP(3-30), and their use as antagonists of the GIP receptor and for treatment of disorders such as obesity, diabetes mellitus and insulin resistance.
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
The present disclosure is directed to systems for in vivo tracking of target cells resulting from implantation of a preparation of cells. The present disclosure is further directed to in vivo methods of tracking a preparation of cells implanted in a subject, and of preparations of cells.
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
